The Human Phenotype Ontology (HPO) provides the following list of features that have been reported in people with this condition. Much of the information in the HPO comes from Orphanet, a European rare disease database. If available, the list includes a rough estimate of how common a feature is (its frequency). Frequencies are based on a specific study and may not be representative of all studies. You can use the MedlinePlus Medical Dictionary for definitions of the terms below.
|Signs and Symptoms||Approximate number of patients (when available)|
|Abnormality of eosinophils||90%|
|Congestive heart failure||90%|
|Abnormality of the pericardium||50%|
|Abnormality of the pleura||50%|
|Feeding difficulties in infancy||50%|
|Hypopigmented skin patches||50%|
|Nausea and vomiting||50%|
|Abnormality of temperature regulation||7.5%|
|Abnormality of the endocardium||7.5%|
|Coronary artery disease||7.5%|
|Cranial nerve paralysis||7.5%|
Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.
Nonprofit support and advocacy groups bring together patients, families, medical professionals, and researchers. These groups often raise awareness, provide support, and develop patient-centered information. Many are the driving force behind research for better treatments and possible cures. They can direct people to research, resources, and services. Many groups also have experts who serve as medical advisors. Visit their website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD. Suggest an organization to add.
Living with a genetic or rare disease can impact the daily lives of patients and families. These resources can help families navigate various aspects of living with a rare disease.
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
8th International Eosinophil Society’s Biennial Symposium
Saturday, July 13, 2013 -
Wednesday, July 17, 2013
Location: Oxford, England
Description: IES Symposium organizers’ central goal is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of allergy, immunology, hematology, and cancer in relation to the role of the eosinophil in health and disease.
Contact: Michael Minnicozzi, Ph.D., (301) email@example.com
Co-funding Institute(s): National Institute of Allergy and Infectious Diseases, Office of Rare Diseases Research
Eosinophil-Associated Disease: Approaches to Treatment Wednesday, May 25, 2005 -
Thursday, May 26, 2005
Location: University Hospital, Bern, Switzerland
Description: Idiopathic hypereosinophilic syndromes (HESs), including idiopathic HES, familial hypereosinophilia, Churg-Strauss vasculitis, and eosinophil-associated gastrointestinal disorders (EGID), are a heterogeneous group of rare disorders that are characterized by marked eosinophilia in the peripheral blood and/or tissues without identifiable cause. The goals of this conference were to bring together clinicians and scientists with expertise in the treatment of the various idiopathic hypereosinophilic disorders in order to summarize and discuss available data on efficacy and side effects of the therapeutic agents and modalities currently in use for the treatment of selected HESs, with the goal of identifying a consensus approach; to identify novel agents and/or strategies for use in future clinical trials; and to continue to expand the consortium of clinical researchers and available resources for collaborative study established at the prior workshop on the diagnosis of eosinophilic disorders in order to foster the development of multicenter protocols to study the pathogenesis and treatment of idiopathic hypereosinophilic disorders. Participants addressed the state of currently available therapies for three idiopathic HESs, taking into account recent developments in diagnostic testing, advances in the understanding of the pathogenesis of hypereosinophilic conditions, and novel strategies for the treatment of idiopathic eosinophilic disorders.
Contact: Amy Klion, M.D.,(301) 435-8903,firstname.lastname@example.org
Co-funding Institute(s): National Institute of Allergy and Infectious Diseases
Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know. Submit a new question
My wife was diagnosed with Churg Strauss about 9 years ago but lately she has red itchy rashes and spots on her back, arms and legs. Is that a symptom of Churg Strauss coming back? See answer